77 related articles for article (PubMed ID: 9216710)
1. Intensified M-VEC chemotherapy with G-CSF support as outpatient treatment for advanced bladder cancer.
Pronzato P; Bertelli G; Bruna F; Tani F; Vaira F; Vanoli M; Vigani A
Anticancer Res; 1997; 17(3C):2325-7. PubMed ID: 9216710
[TBL] [Abstract][Full Text] [Related]
2. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
3. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study.
Petrioli R; Frediani B; Manganelli A; Barbanti G; De Capua B; De Lauretis A; Salvestrini F; Mondillo S; Francini G
Cancer; 1996 Jan; 77(2):344-51. PubMed ID: 8625244
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
Lehmann J; Retz M; Wiemers C; Beck J; Thüroff J; Weining C; Albers P; Frohneberg D; Becker T; Funke PJ; Walz P; Langbein S; Reiher F; Schiller M; Miller K; Roth S; Kälble T; Sternberg D; Wellek S; Stöckle M;
J Clin Oncol; 2005 Aug; 23(22):4963-74. PubMed ID: 15939920
[TBL] [Abstract][Full Text] [Related]
5. [Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
Rassweiler J; Rüther U; Bäuerle K; Bub P; Jipp P; Eisenberger F
Urologe A; 1989 Jan; 28(1):25-30. PubMed ID: 2922897
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
7. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
9. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
Lehmann J; Franzaring L; Thüroff J; Wellek S; Stöckle M
BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
[TBL] [Abstract][Full Text] [Related]
10. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.
Lin CC; Hsu CH; Huang CY; Cheng AL; Chen J; Vogelzang NJ; Pu YS
Cancer; 2006 Mar; 106(6):1269-75. PubMed ID: 16470604
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
Bellmunt Molins J; Ribas A; Albanell J; Lorente Garín JA; de Torres Mateos JA; Morote Robles J; López Palacios MA; Banús Gassol JM; Casado Cobo S; Eres N; Solé Calvo LA
Arch Esp Urol; 1996 Jun; 49(5):465-72. PubMed ID: 8766083
[TBL] [Abstract][Full Text] [Related]
12. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
Seguchi T; Nakano E; Miki T; Kondoh M; Nishimura K; Nakamura N; Okuyama A
Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
[TBL] [Abstract][Full Text] [Related]
15. Sequential high dose-density chemotherapy with two active regimens for advanced small cell lung cancer.
Vigani A; Pensa F; Vaira F; Bancalari L; Cordani S; Maggiani R; Canessa P; Pronzato P
Anticancer Res; 2000; 20(5C):4015-8. PubMed ID: 11268494
[TBL] [Abstract][Full Text] [Related]
16. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].
Fukuda H; Mitsumori K; Minagawa S; Kumazawa T; Tadachi K; Iinuma M; Satoh S; Satoh K; Habuchi T; Kato T
Hinyokika Kiyo; 2005 Feb; 51(2):113-6. PubMed ID: 15773365
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
[TBL] [Abstract][Full Text] [Related]
18. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Tsai YS; Tzai TS; Chow NH
Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
[TBL] [Abstract][Full Text] [Related]
19. [Dose intensity in M-VAC chemotherapy with rG-CSF for metastatic transitional urothelial cancer].
Obata K; Kobayashi H; Takaba H; Yokoi K; Hikosaka A
Hinyokika Kiyo; 1994 Oct; 40(10):939-44. PubMed ID: 7527613
[TBL] [Abstract][Full Text] [Related]
20. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]